ReviewDrug design, development and therapy2023

Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn's Disease: Patient Selection and Reported Outcomes.

Sara Horst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.